How the liver responds to sugar given by vein during weight-loss surgery
Tests liver response to intravenous sugar in people with obesity, with or without fatty liver.
Plain-language title generated from the registry record
Registry title: Hepatic Gene Response to Intravenous Glucose in Obese Patients With and Without MASLD Undergoing Bariatric Surgery
Key facts
- Where
- Amsterdam, NetherlandsSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 65 years old?
Source: NCT07326865, who can take part
Where in Netherlands
- AMCAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Trial code
- NCT07326865
- Record updated
- 8 January 2026
- Original description
The goal of this clinical trial is to learn how the liver responds to sugar in people with obesity who are having bariatric surgery. Researchers want to understand differences between people with and without metabolic associated steatotic liver disease (MASLD).Read full original descriptionShow less
Glucose IV and Its Hepatic Outcomes After a Metabolic Stress Test During Bariatric Surgery in Obese Patients With and Without MASLD
The goal of this clinical trial is to learn how the liver responds to sugar in people with obesity who are having bariatric surgery. Researchers want to understand differences between people with and without metabolic associated steatotic liver disease (MASLD).
The main question is:
Does giving sugar directly into the vein change how liver genes work in people with and without MASLD?
Researchers will compare:
* People with MASLD who receive sugar * People with MASLD who receive saline (salt water) * People without MASLD who receive sugar * People without MASLD who receive saline
During surgery, participants will:
* Receive either a sugar solution (35 grams of glucose in 150 mL fluid) or saline * Have small samples (biopsies) taken from the liver and fat tissue before and 45 minutes after the infusion * Provide blood samples to measure sugar, insulin, and other metabolites * Provide a one-time sample of intestinal tissue that is normally removed during surgery
This study may help explain why MASLD develops and how the liver reacts to sugar. The results could lead to new ways to understand and treat liver disease in people with obesity.
Inclusion: To be eligible to participate in this study, a subject must meet all of the following criteria:; Adult individuals, age >35 < 65 years old. Stable weight (no more than 3% TWL of initial body weight from screening to surgery) Subjects should be able to give informed consent Subjects agree to have tissue biopsies performed during surgery, that is 2 liver, subcutaneous, visceral and omental biopsies plus a one-time jejunal biopsy; For obese non-MASLD patients:; Adult individuals, age >35 < 65 years old; BMI ≥ 40 kg/m², or a BMI ≥ 35 kg/m² with an obesity-related comorbidity; No MASLD based on Fibroscan; Estimated glomerular filtration rate (eGFR) > 60mL/min/1.73m2; For obese MASLD patients:; MASLD diagnosis according to Fibroscan; Compensated liver disease with the following hematologic and biochemical criteria on entry into study:; ALAT <10x ULN; Hemoglobin > 11g/dL for females and 12 g/dL for males; White blood cell (WBC) > 2.5 K/ μL; Neutrophil count > 1.5 K μL; Platelets > 100 K/μL; Total bilirubin <35 μmol/L; Albumin >30 g/L; TP >80% or INR <1.4; Serum creatinine <1.3 mg/dL (men) or <1.1 mg/dL (women) or; Estimated glomerular filtration rate (eGFR) > 60mL/min/1.73m2.
Exclusion: Hemostasis disorders or current treatment with anticoagulants; Primary lipid disorder; All medical and psychiatric conditions except for obesity related diseases; Uncontrolled hypertension (RR > 150/95 mmHg); Evidence of another form of liver disease; History of sustained excess alcohol ingestion: daily consumption >30g/day (3 drinks per day) for males and >20 g/day (2 drinks per day) for females; Significant systemic or major illnesses other than liver disease, including congestive heart failure (class C and D of the AHA), unstable coronary artery disease, cerebrovascular disease, pulmonary disease, kidney failure, organ transplantation, serious psychiatric disease, active malignancy, compromised immunity; Type 1 or type 2 diabetes; Known heart failure; Contra-indication for liver biopsy History of/or current cardiac dysrhythmias and/or a history of cardiovascular events including myocardial infarction, except patients with only well-controlled hypertension; Known genetic basis for insulin resistance or glucose intolerance; Chronic kidney disease (creatinine > 150 umol/L); A potential subject who meets any of the following criteria will be excluded from participation in this study:; Use of metformin and SGLT2/ exogenous insulin/GLP-1 RA; Pregnancy, females who are breastfeeding; Body mass index (BMI) >45 kg/m2.